Yuhan Corp. announced on Nov. 7 that it has signed a joint research agreement with Cyclica, a Canadian biotech company.
Through the deal, the Korean company can use Cyclica's advanced artificial intelligence (AI)-based candidate discovery platform. It is expected to be able to secure new drug candidates suitable for its two selected R&D programs early.
Cyclica's platform differs from other AI drug development platforms in that it selects candidates by considering their pharmacological, physicochemical and pharmacokinetic characteristics.
Under the joint research agreement, Cyclica will receive a down payment and milestone payments, which are paid when achievements are made.
In addition, Yuhan Corp. and Cyclica plan to discover new drug candidates and strengthen R&D in areas where a treatment has not yet been developed.